Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.
Nat. Biotechnol. 33, 51-57 (2015)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with substantial heterogeneity in its clinical presentation. This makes diagnosis and effective treatment difficult, so better tools for estimating disease progression are needed. Here, we report results from the DREAM-Phil Bowen ALS Prediction Prize4Life challenge. In this crowdsourcing competition, competitors developed algorithms for the prediction of disease progression of 1,822 ALS patients from standardized, anonymized phase 2/3 clinical trials. The two best algorithms outperformed a method designed by the challenge organizers as well as predictions by ALS clinicians. We estimate that using both winning algorithms in future trial designs could reduce the required number of patients by at least 20%. The DREAM-Phil Bowen ALS Prediction Prize4Life challenge also identified several potential nonstandard predictors of disease progression including uric acid, creatinine and surprisingly, blood pressure, shedding light on ALS pathobiology. This analysis reveals the potential of a crowdsourcing competition that uses clinical trial data for accelerating ALS research and development.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
39.080
5.304
118
142
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Uric-acid Levels; Body-mass Index; Functional Rating-scale; Alsfrs-r Score; Disease Progression; Prognostic-factors; Parkinson-disease; Blood-pressure; Survival; Population
Sprache
englisch
Veröffentlichungsjahr
2015
Prepublished im Jahr
2014
HGF-Berichtsjahr
2014
ISSN (print) / ISBN
1087-0156
e-ISSN
1546-1696
Zeitschrift
Nature Biotechnology
Quellenangaben
Band: 33,
Heft: 1,
Seiten: 51-57
Verlag
Nature Publishing Group
Verlagsort
New York, NY
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30505 - New Technologies for Biomedical Discoveries
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-503700-001
PubMed ID
25362243
DOI
10.1038/nbt.3051
WOS ID
WOS:000347714200027
Scopus ID
84963940835
Erfassungsdatum
2014-11-17